All In Biotech

Drug Trial Radar · NCT03742908

Application of Intra-operative Prophylactic Antibiotics/Antiseptics in Chinese Breast Reconstruction Patients

A Single Center Prospective Randomized Control Trial Investigating the Short-term and Long-term Effects of Intraoperative Prophylactic Antibiotics/Antiseptics on Surgical Outcomes in Chinese Post-mastectomy Breast Reconstruction Patients

Last checked: Nov 20, 2026Latest source record: Nov 15, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 291 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

291

Planned (sponsor's estimate)

Start

Jun 16, 2018

Primary completion

Oct 31, 2021

Study completion Oct 31, 2021

Sponsor

Lead sponsor
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 15, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to investigate different approaches of local application of antibiotics/antiseptics intraoperatively in Chinese patients undergoing post-mastectomy implant based breast reconstruction, and aims to single out an intervention method that limits the use of antibiotics and maintains low rates of surgical site infection and capsular contracture. Patients who undergo post mastectomy breast reconstruction in the breast reconstruction department in Tianjin Medical University Cancer Institute and Hospital are eligible to enter the study.

Conditions

  • Breast Neoplasms

Interventions

  • Cefazolin/clindamycinDrug

    Local implant immersion and/or breast pocket irrigation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of minor surgical site infectionTime frame: assessed up to 3 months post-op
  2. Occurrence of major surgical site infectionTime frame: assessed up to 3 months post-op
  3. Occurrence of capsular contractureTime frame: assessed from 3 months post-op up to 2 years post-op or until the trial ends, whichever comes first

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.